Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 144 |
| Other | 6 |
| Supportive Care | 6 |
| Basic Science | 5 |
| Diagnostic | 4 |
| Prevention | 4 |
| NA | 2 |
| Screening | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 284 |
| interventional | 172 |
| Observational | 98 |
| Registry | 14 |
```
| intervention_type | Study_Count |
|---|---|
| Drug|placebo | 65 |
| Drug | 51 |
| Other | 14 |
| Biological|placebo | 10 |
| Biological | 8 |
| Behavioral | 6 |
| Diagnostic Test | 4 |
| Dietary Supplement | 3 |
| Procedure | 3 |
| Biological|Procedure | 2 |
| Biological|Drug | 1 |
| Biological|Drug|placebo | 1 |
| Device | 1 |
| Dietary Supplement|placebo | 1 |
| Genetic|placebo | 1 |
| placebo | 1 |
| Country | Study_Count |
|---|---|
| United States | 27 |
| NA | 16 |
| United Kingdom | 8 |
| Denmark | 7 |
| Japan | 5 |
| China | 4 |
| Germany | 4 |
| France | 3 |
| Norway | 3 |
| Belgium|Bulgaria|Czechia|Estonia|Poland|Spain|Ukraine | 2 |
| Brazil | 2 |
| Canada | 2 |
| Egypt | 2 |
| Germany|Netherlands|United Kingdom | 2 |
| Netherlands | 2 |
| Sweden | 2 |
| United States|Canada | 2 |
| United States|Czechia|Germany|Hungary|Poland|Russian Federation | 2 |
| United States|Puerto Rico | 2 |
| Argentina|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Hungary|India|Israel|Italy|Mexico|Netherlands|Poland|South Africa|Spain|Sweden|Switzerland|Ukraine|United Kingdom | 1 |
| Argentina|Australia|Austria|Belgium|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Saudi Arabia|Serbia|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom | 1 |
| Australia|Bulgaria|Czechia|Estonia|Hungary|Lithuania|Poland|Russian Federation|Serbia|Slovakia|Spain | 1 |
| Bangladesh | 1 |
| Belarus|Russian Federation | 1 |
| Belgium | 1 |
| Belgium|Bosnia and Herzegovina|Bulgaria|Czechia|Estonia|Georgia|Latvia|Poland|Spain|Ukraine | 1 |
| Belgium|Bulgaria|Czechia|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom | 1 |
| Belgium|Bulgaria|France|Germany|Greece|Hungary|Israel|Italy|Poland|Portugal|Russian Federation|Spain|Ukraine|United Kingdom | 1 |
| Belgium|Canada|Germany|Netherlands|United Kingdom | 1 |
| Bulgaria|Czechia|Germany|Greece|Italy|Slovakia|Spain|United Kingdom | 1 |
| Bulgaria|Estonia|Hungary|Poland|Russian Federation|Ukraine | 1 |
| Bulgaria|Moldova, Republic of|United Kingdom | 1 |
| Canada|United States|Australia|Belgium|Germany|Hungary|Italy|Japan|Poland|Russian Federation|United Kingdom | 1 |
| Colombia|United States|Argentina|Brazil|Canada|Chile|Czechia|France|Germany|Greece|Israel|Italy|Mexico|Peru|Poland|South Africa|Spain | 1 |
| Denmark|Finland|Norway|Sweden | 1 |
| France|Germany|United States|Argentina|Belgium|Brazil|Canada|Czechia|Hungary|Ireland|Italy|Mexico|Poland|Spain|United Kingdom | 1 |
| Germany|United States|Australia|Canada|Czechia|Italy|Japan|Poland|Russian Federation|United Kingdom | 1 |
| Hong Kong | 1 |
| Hungary|Italy|United States|Argentina|Australia|Canada|Czechia|Germany|Mexico|Poland|Russian Federation|South Africa|Spain | 1 |
| India | 1 |
| Lithuania|United States|Australia|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Hungary|Italy|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Taiwan|United Kingdom | 1 |
| Mexico|United States|Argentina|Hungary|Poland|Russian Federation|Spain|Ukraine | 1 |
| Portugal | 1 |
| Russian Federation|United States|Australia|Belarus|Canada|Germany|Hungary|Lithuania|Poland|Romania|Spain|Ukraine | 1 |
| Switzerland|United States|France|Netherlands | 1 |
| Turkey | 1 |
| United States|Argentina|Australia|Belarus|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Chile|China|Colombia|Croatia|Czechia|Estonia|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Norway|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|Singapore|Slovakia|Slovenia|South Africa|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Chile|Croatia|Czechia|Denmark|Estonia|Finland|Germany|Greece|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czech Republic|Germany|Israel|Italy|Philippines|Poland|Romania|Russian Federation|Singapore|Slovakia|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|Germany|Israel|Italy|Philippines|Poland|Russian Federation|Singapore|Slovakia|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Singapore|South Africa|Spain|Sweden|United Kingdom | 1 |
| United States|Argentina|Austria|Belgium|Canada|Colombia|Czechia|France|Germany|Hungary|Ireland|Italy|Mexico|Netherlands|Norway|Spain|United Kingdom | 1 |
| United States|Argentina|Austria|Canada|Chile|Czechia|Denmark|Estonia|Finland|Germany|Greece|Guatemala|Hungary|India|Ireland|Israel|Italy|Latvia|Lithuania|Mexico|Netherlands|Philippines|Russian Federation|Spain|Sweden|Thailand|United Kingdom|Vietnam | 1 |
| United States|Australia|Austria|Canada|Finland|Germany|Hungary|Latvia|Lithuania|New Zealand|Poland|Russian Federation|Spain|United Kingdom | 1 |
| United States|Australia|Austria|Canada|France|Germany|Hungary|New Zealand|Poland|Russian Federation|South Africa|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Canada|Chile|Czechia|France|Greece|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Portugal|Puerto Rico|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Czechia|France|Germany|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Bulgaria|Canada|Czechia|France|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Bulgaria|Canada|Czechia|France|Germany|Italy|Poland|Russian Federation|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Czechia|Estonia|Germany|Hungary|Latvia|Netherlands|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Japan|Poland|Russian Federation|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Czechia|Germany|Poland|Puerto Rico|Russian Federation|Thailand|United Kingdom | 1 |
| United States|Australia|Brazil|Bulgaria|Canada|Colombia|Czechia|Germany|Italy|Poland|Puerto Rico|Qatar|Spain|United Kingdom | 1 |
| United States|Australia|Bulgaria|Canada|Czechia|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|Iceland|India|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Netherlands|Poland|Portugal|Russian Federation|Slovakia|Spain|United Kingdom | 1 |
| United States|Australia|Bulgaria|Canada|Czechia|Germany|Italy|Netherlands|Puerto Rico|Russian Federation|Spain|Switzerland|United Kingdom | 1 |
| United States|Australia|Canada|Czechia|Estonia|Hungary|New Zealand|Romania|Russian Federation|Spain | 1 |
| United States|Australia|Canada|Czechia|Germany|Hungary|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Taiwan|Ukraine | 1 |
| United States|Australia|Canada|Czechia|Germany|Japan|Poland|Russian Federation | 1 |
| United States|Australia|Canada|Finland|France|Germany|Italy|Korea, Republic of|Lithuania|Poland|Romania|Russian Federation|Slovakia|Spain|Switzerland|United Kingdom | 1 |
| United States|Australia|Canada|Germany|Hungary|Korea, Republic of|Poland|Russian Federation|United Kingdom | 1 |
| United States|Australia|Czechia|France|Germany|Italy|Poland|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|New Zealand | 1 |
| United States|Austria|Belgium|Canada|Denmark|Germany|Italy|Russian Federation|Spain|Switzerland|United Kingdom | 1 |
| United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Russian Federation|Spain|United Kingdom | 1 |
| United States|Austria|Canada|France|Germany|Hungary|Poland|Russian Federation|Sweden|United Kingdom | 1 |
| United States|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Germany|Hungary|Italy|Poland|Russian Federation|South Africa|Spain|Taiwan|United Kingdom | 1 |
| United States|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Japan|Mexico|Netherlands|Poland|Russian Federation|Spain|Ukraine|United Kingdom | 1 |
| United States|Belgium|Canada|Denmark|France|Germany|Hungary | 1 |
| United States|Belgium|Canada|Poland|Spain|United Kingdom | 1 |
| United States|Belgium|Germany|Italy|Poland|Russian Federation|South Africa|Spain|Turkey|United Kingdom | 1 |
| United States|Belgium|Germany|Italy|Poland|Russian Federation|Spain|Turkey | 1 |
| United States|Bulgaria|Czechia|Estonia|Latvia|Lithuania|Malaysia|Poland|Russian Federation|Spain|Taiwan|Turkey|Ukraine | 1 |
| United States|Bulgaria|Czechia|Estonia|Mexico|Poland|Russian Federation|Slovakia|South Africa|Spain|Ukraine|United Kingdom | 1 |
| United States|Canada|Denmark|Finland|Switzerland | 1 |
| United States|Canada|France|Germany|Greece|Hungary|Latvia|Mexico|Poland|Russian Federation | 1 |
| United States|Canada|Germany|Poland|Romania|Russian Federation|Spain | 1 |
| United States|Canada|Germany|Poland|Russian Federation | 1 |
| United States|Czechia|Germany|Hungary|Italy|Poland|Russian Federation|Spain|United Kingdom | 1 |
| United States|Czechia|Germany|Poland|Russian Federation | 1 |
| United States|Czechia|Russian Federation | 1 |
| United States|Hungary|Argentina|Bulgaria|Canada|Chile|Czechia|France|Greece|Latvia|Mexico|Poland|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|United Kingdom | 1 |
| United States|Japan | 1 |
| United States|Netherlands|Switzerland | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 63 |
| 2 | 11 |
| 3 | 3 |
| 4 | 3 |
| 6 | 2 |
| 7 | 2 |
| 8 | 2 |
| 9 | 3 |
| 10 | 2 |
| 11 | 2 |
| 13 | 1 |
| 16 | 2 |
| 18 | 2 |
| 19 | 1 |
| 21 | 1 |
| 22 | 2 |
| 25 | 3 |
| 27 | 1 |
| 30 | 2 |
| 32 | 1 |
| 33 | 1 |
| 34 | 1 |
| 36 | 1 |
| 38 | 1 |
| 40 | 1 |
| 41 | 2 |
| 42 | 2 |
| 44 | 1 |
| 45 | 1 |
| 48 | 1 |
| 49 | 1 |
| 52 | 1 |
| 53 | 1 |
| 56 | 1 |
| 57 | 1 |
| 59 | 1 |
| 60 | 1 |
| 64 | 1 |
| 71 | 1 |
| 73 | 1 |
| 76 | 1 |
| 77 | 2 |
| 82 | 3 |
| 83 | 1 |
| 88 | 1 |
| 89 | 1 |
| 91 | 1 |
| 92 | 3 |
| 94 | 1 |
| 95 | 1 |
| 98 | 1 |
| 101 | 1 |
| 103 | 1 |
| 105 | 2 |
| 106 | 1 |
| 109 | 2 |
| 116 | 1 |
| 117 | 3 |
| 118 | 1 |
| 123 | 1 |
| 125 | 1 |
| 131 | 1 |
| 138 | 2 |
| 139 | 1 |
| 153 | 1 |
| 155 | 1 |
| 165 | 1 |
| 168 | 1 |
| 172 | 1 |
| 257 | 1 |
| 347 | 1 |
| Phase | Study_Count |
|---|---|
| Phase 3 | 73 |
| N/A | 32 |
| Phase 2 | 29 |
| Phase 4 | 21 |
| Phase 1 | 14 |
| Early Phase 1 | 1 |
| Phase 1/Phase 2 | 1 |
| Phase 2/Phase 3 | 1 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 28 |
| 2 | 74 |
| 3 | 26 |
| 4 | 16 |
| 5 | 9 |
| 6 | 4 |
| 7 | 2 |
| 25 | 1 |
| NA | 12 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 68 | 13.0000 | 6.00000 | 120 | 20.0000 | 540 | 51.0000 | 10.00 |
| 1st Qu. | 68 | 55.7500 | 20.25000 | 120 | 122.0000 | 540 | 195.0000 | 48.00 |
| Median | 68 | 100.0000 | 41.00000 | 120 | 180.0000 | 540 | 390.0000 | 115.00 |
| Mean | 68 | 715.4062 | 56.85714 | 120 | 173.4828 | 540 | 395.6164 | 237.15 |
| 3rd Qu. | 68 | 209.2500 | 51.25000 | 120 | 217.0000 | 540 | 489.0000 | 318.75 |
| Max. | 68 | 18000.0000 | 216.00000 | 120 | 617.0000 | 540 | 1705.0000 | 1013.00 |
| group_type | Group_Count |
|---|---|
| Experimental | 248 |
| Placebo Comparator | 77 |
| Active Comparator | 65 |
| Other | 27 |
| NA | 12 |
| No Intervention | 8 |
| Sham Comparator | 1 |
| intervention_model | Study_Count |
|---|---|
| Parallel Assignment | 124 |
| Single Group Assignment | 40 |
| Crossover Assignment | 5 |
| NA | 2 |
| Factorial Assignment | 1 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 144 |
| Other | 6 |
| Supportive Care | 6 |
| Basic Science | 5 |
| Diagnostic | 4 |
| Prevention | 4 |
| NA | 2 |
| Screening | 1 |
| Country | Study_Count |
|---|---|
| NA | 18 |
| France | 12 |
| United States | 12 |
| United Kingdom | 7 |
| Germany | 6 |
| Canada | 5 |
| Spain | 4 |
| Italy | 3 |
| Australia | 2 |
| Austria | 2 |
| Belgium | 2 |
| Denmark | 2 |
| Japan | 2 |
| Korea, Republic of | 2 |
| Netherlands | 2 |
| Russian Federation | 2 |
| Sweden | 2 |
| Australia|China|Korea, Republic of | 1 |
| Belgium|France|Greece|Netherlands|Russian Federation|Spain|United Kingdom | 1 |
| Bulgaria|Canada|Czechia|Germany|Greece|Spain|United Kingdom | 1 |
| Colombia | 1 |
| Croatia|Hungary|Israel|Poland|Romania|Slovakia|Ukraine | 1 |
| Germany|United Kingdom | 1 |
| Greece | 1 |
| Norway | 1 |
| Philippines | 1 |
| Portugal | 1 |
| Saudi Arabia|Kuwait|Qatar|Algeria|Egypt | 1 |
| Turkey | 1 |
| United States|Argentina|Australia|Austria|Belgium|Canada|Chile|Colombia|Czechia|Greece|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Portugal|Slovakia|Slovenia|Spain|Sweden|Taiwan|Ukraine | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 62 |
| 2 | 3 |
| 3 | 1 |
| 4 | 3 |
| 5 | 1 |
| 8 | 1 |
| 9 | 3 |
| 10 | 2 |
| 12 | 1 |
| 14 | 1 |
| 15 | 3 |
| 19 | 1 |
| 20 | 1 |
| 21 | 1 |
| 22 | 2 |
| 38 | 1 |
| 41 | 1 |
| 43 | 1 |
| 47 | 1 |
| 68 | 1 |
| 77 | 1 |
| 80 | 1 |
| 163 | 1 |
| 180 | 1 |
| 432 | 1 |
| 509 | 1 |
| 634 | 1 |
| Measure | Observational |
|---|---|
| Min | 12.000 |
| 1st Qu | 107.000 |
| Median | 250.000 |
| Mean | 3901.433 |
| 3rd Qu | 809.000 |
| Max | 266890.000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 65 |
| Case-Only | 15 |
| Case-Control | 7 |
| NA | 6 |
| Case Control | 2 |
| Other | 2 |
| Case-Crossover | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 81 |
| Cross-Sectional | 8 |
| Retrospective | 5 |
| NA | 2 |
| Cross-Sectional, Retrospective/Prospective | 1 |
| Other | 1 |
| Country | Study_Count |
|---|---|
| United States | 4 |
| Denmark | 3 |
| Australia | 1 |
| Brazil|Canada|United States|Austria|Estonia|France|Germany|Italy|Romania|Russian Federation|Singapore|Spain|Turkey|United Kingdom | 1 |
| Canada | 1 |
| Germany | 1 |
| Italy | 1 |
| Korea, Republic of | 1 |
| NA | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 10 |
| 3 | 1 |
| 11 | 1 |
| 22 | 2 |
| Measure | Registries |
|---|---|
| Min | 110.000 |
| 1st Qu | 356.500 |
| Median | 4250.000 |
| Mean | 8165.429 |
| 3rd Qu | 6500.000 |
| Max | 57053.000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 11 |
| Case-Control | 1 |
| Case-Only | 1 |
| Other | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 12 |
| Cross-Sectional | 1 |
| Other | 1 |
| target_duration | Study_Count |
|---|---|
| 10 Years | 3 |
| 2 Years | 2 |
| 5 Years | 2 |
| 1 Day | 1 |
| 12 Months | 1 |
| 15 Years | 1 |
| 16 Weeks | 1 |
| 24 Years | 1 |
| 3 Years | 1 |
| 6 Months | 1 |
#If less then 500 trials
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03733925 | A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03733925 | Recruiting | Johnson & Johnson Private Limited | 2021-01-25 |
| NCT04314544 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | https://ClinicalTrials.gov/show/NCT04314544 | Recruiting | Sun Pharma Global FZE | 2021-08-11 |
| NCT04314531 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | https://ClinicalTrials.gov/show/NCT04314531 | Recruiting | Sun Pharma Global FZE | 2021-05-12 |
| NCT04163016 | A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) | https://ClinicalTrials.gov/show/NCT04163016 | Recruiting | UCB Pharma | 2022-08-31 |
| NCT04109976 | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT04109976 | Enrolling by invitation | UCB Pharma | 2021-01-31 |
| NCT04009499 | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT04009499 | Enrolling by invitation | UCB Pharma | 2024-10-31 |
| NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy | https://ClinicalTrials.gov/show/NCT03796858 | Active, not recruiting | Janssen Pharmaceutica N.V., Belgium | 2020-11-30 |
| NCT03486457 | Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03486457 | Recruiting | Pfizer | 2021-06-30 |
| NCT03410992 | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | https://ClinicalTrials.gov/show/NCT03410992 | Active, not recruiting | UCB Pharma | 2018-12-28 |
| NCT03409211 | Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03409211 | Recruiting | NYU Langone Health | 2023-12-31 |
| NCT03402087 | A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients | https://ClinicalTrials.gov/show/NCT03402087 | Completed | Bristol-Myers Squibb | 2018-03-20 |
| NCT03370133 | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | https://ClinicalTrials.gov/show/NCT03370133 | Completed | UCB Pharma | 2019-01-08 |
| NCT03320876 | An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. | https://ClinicalTrials.gov/show/NCT03320876 | Active, not recruiting | Galapagos NV | 2024-01-31 |
| NCT03262727 | The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients | https://ClinicalTrials.gov/show/NCT03262727 | Completed | Bristol-Myers Squibb | 2017-11-23 |
| NCT03254784 | A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation | https://ClinicalTrials.gov/show/NCT03254784 | Completed | Bristol-Myers Squibb | 2017-11-04 |
| NCT03248518 | Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases | https://ClinicalTrials.gov/show/NCT03248518 | Active, not recruiting | University of Aberdeen | 2020-10-31 |
| NCT03162796 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) | https://ClinicalTrials.gov/show/NCT03162796 | Completed | Janssen Research & Development, LLC | 2019-03-14 |
| NCT03158285 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03158285 | Active, not recruiting | Janssen Research & Development, LLC | 2019-02-25 |
| NCT03151551 | A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03151551 | Completed | Eli Lilly and Company | 2018-11-15 |
| NCT03148860 | Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA | https://ClinicalTrials.gov/show/NCT03148860 | Recruiting | Fraunhofer Institute for Molecular Biology and Applied Ecology | 2020-12-30 |
| NCT03142503 | The DIET Trial - Dietetic Intervention in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03142503 | Completed | Federal University of São Paulo | 2015-03-16 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug | https://ClinicalTrials.gov/show/NCT03104400 | Active, not recruiting | AbbVie | 2019-09-20 |
| NCT03104374 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug | https://ClinicalTrials.gov/show/NCT03104374 | Active, not recruiting | AbbVie | 2019-07-17 |
| NCT03101670 | A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03101670 | Completed | Galapagos NV | 2018-03-12 |
| NCT03058900 | Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03058900 | Active, not recruiting | Odense University Hospital | 2020-07-01 |
| NCT03031782 | Secukinumab Safety and Efficacy in JPsA and ERA | https://ClinicalTrials.gov/show/NCT03031782 | Active, not recruiting | Novartis | 2020-06-16 |
| NCT03008590 | Low Dose Naltrexone for Chronic Pain From Arthritis | https://ClinicalTrials.gov/show/NCT03008590 | Completed | VA Office of Research and Development | 2019-12-31 |
| NCT02995460 | Interval Training Study in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02995460 | Completed | Norwegian University of Science and Technology | 2015-12-31 |
| NCT02986373 | A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) | https://ClinicalTrials.gov/show/NCT02986373 | Completed | AbbVie | 2018-07-08 |
| NCT02986139 | Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02986139 | Completed | Amgen | 2017-09-08 |
| NCT02980692 | Efficacy and Safety Study of SUNPG1623 | https://ClinicalTrials.gov/show/NCT02980692 | Completed | Sun Pharma Global FZE | 2019-03-01 |
| NCT02969525 | A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis. | https://ClinicalTrials.gov/show/NCT02969525 | Completed | UCB Pharma | 2017-11-30 |
| NCT02917434 | Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02917434 | Active, not recruiting | Vastra Gotaland Region | 2019-12-12 |
| NCT02912221 | Stepping Up For Inflammatory Arthritis | https://ClinicalTrials.gov/show/NCT02912221 | Active, not recruiting | University of Pennsylvania | 2020-11-30 |
| NCT02854163 | Effect of Secukinumab in the Treatment of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02854163 | Completed | University of Liverpool | 2019-09-18 |
| NCT02814175 | A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) | https://ClinicalTrials.gov/show/NCT02814175 | Completed | AbbVie | 2019-09-23 |
| NCT02798211 | Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo | https://ClinicalTrials.gov/show/NCT02798211 | Completed | Novartis | 2018-12-05 |
| NCT02772601 | This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02772601 | Completed | AbbVie | 2017-06-15 |
| NCT02771210 | Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site | https://ClinicalTrials.gov/show/NCT02771210 | Completed | Novartis | 2019-12-11 |
| NCT02745080 | Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02745080 | Completed | Novartis | 2019-12-30 |
| NCT02721966 | Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement | https://ClinicalTrials.gov/show/NCT02721966 | Completed | Novartis | 2019-06-26 |
| NCT02719171 | BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02719171 | Completed | AbbVie | 2017-05-31 |
| NCT02714322 | MYL-1401A Efficacy and Safety Comparability Study to Humira® | https://ClinicalTrials.gov/show/NCT02714322 | Completed | Mylan Inc. | 2016-05-31 |
| NCT02662985 | Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT02662985 | Recruiting | Novartis | 2020-11-23 |
| NCT02598739 | Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02598739 | Completed | Federal University of São Paulo | 2014-09-30 |
| NCT02584855 | A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02584855 | Completed | Eli Lilly and Company | 2018-10-30 |
| NCT03926195 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis | https://ClinicalTrials.gov/show/NCT03926195 | Recruiting | Galapagos NV | 2021-01-31 |
| NCT02538341 | Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) | https://ClinicalTrials.gov/show/NCT02538341 | Active, not recruiting | University of Alabama at Birmingham | 2019-01-31 |
| NCT02483234 | Psoriasis-Arthritis & Bone Program | https://ClinicalTrials.gov/show/NCT02483234 | Completed | University of Erlangen-Nürnberg Medical School | 2018-06-30 |
| NCT02436785 | Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? | https://ClinicalTrials.gov/show/NCT02436785 | Completed | University of British Columbia | 2017-12-31 |
| NCT02404350 | Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02404350 | Completed | Novartis | 2017-08-16 |
| NCT02376790 | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02376790 | Completed | Amgen | 2018-01-09 |
| NCT02349451 | A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) | https://ClinicalTrials.gov/show/NCT02349451 | Completed | AbbVie | 2016-07-04 |
| NCT02319759 | Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT02319759 | Completed | Janssen Research & Development, LLC | 2016-05-31 |
| NCT02294227 | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02294227 | Completed | Novartis | 2016-02-16 |
| NCT02267642 | A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02267642 | Completed | AbGenomics B.V Taiwan Branch | 2015-10-31 |
| NCT02232321 | Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study | https://ClinicalTrials.gov/show/NCT02232321 | Completed | Chinese University of Hong Kong | 2017-10-31 |
| NCT02188654 | Metformin in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02188654 | Completed | University of Alexandria | 2014-03-31 |
| NCT02188641 | Effect of Exercise and Diet on Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02188641 | Completed | University of Alexandria | 2014-07-31 |
| NCT02181673 | A Study of Golimumab in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02181673 | Completed | Janssen Research & Development, LLC | 2016-05-05 |
| NCT02164214 | Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? | https://ClinicalTrials.gov/show/NCT02164214 | Completed | Assistance Publique Hopitaux De Marseille | 2015-03-31 |
| NCT02154425 | A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers | https://ClinicalTrials.gov/show/NCT02154425 | Completed | UCB Pharma | 2015-12-31 |
| NCT02148640 | The NOR-SWITCH Study | https://ClinicalTrials.gov/show/NCT02148640 | Completed | Diakonhjemmet Hospital | 2016-06-30 |
| NCT02141763 | Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02141763 | Completed | UCB Pharma | 2015-08-31 |
| NCT02098694 | Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis | https://ClinicalTrials.gov/show/NCT02098694 | Completed | Norwegian University of Science and Technology | 2015-04-30 |
| NCT02065713 | Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients | https://ClinicalTrials.gov/show/NCT02065713 | Completed | Instituto de Medicina Molecular João Lobo Antunes | 2017-06-30 |
| NCT01307423 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT01307423 | Completed | Amgen | 2013-02-21 |
| NCT02052609 | A Phase 3 Clinical Study of KHK 4827 | https://ClinicalTrials.gov/show/NCT02052609 | Completed | Kyowa Kirin Co., Ltd. | 2015-01-28 |
| NCT03896581 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03896581 | Recruiting | UCB Pharma | 2021-02-28 |
| NCT03357471 | Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn’s Disease | https://ClinicalTrials.gov/show/NCT03357471 | Completed | UCB Pharma | 2018-07-02 |
| NCT03895203 | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03895203 | Recruiting | UCB Pharma | 2021-07-31 |
| NCT02349295 | A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02349295 | Completed | Eli Lilly and Company | 2016-09-09 |
| NCT01989468 | 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01989468 | Completed | Novartis | 2015-05-27 |
| NCT01988103 | Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis | https://ClinicalTrials.gov/show/NCT01988103 | Completed | Amgen | 2014-11-20 |
| NCT01976364 | Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01976364 | Completed | Pfizer | 2019-05-20 |
| NCT01925768 | Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01925768 | Completed | Amgen | 2015-02-25 |
| NCT01901185 | Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept | https://ClinicalTrials.gov/show/NCT01901185 | Completed | Amgen | 2013-12-18 |
| NCT01892436 | Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01892436 | Completed | Novartis | 2018-01-11 |
| NCT01882439 | Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors | https://ClinicalTrials.gov/show/NCT01882439 | Completed | Pfizer | 2016-04-30 |
| NCT01871649 | Initial Treatment With Golimumab in Early PsA | https://ClinicalTrials.gov/show/NCT01871649 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2018-11-30 |
| NCT01852851 | Employment and Arthritis: Making it Work | https://ClinicalTrials.gov/show/NCT01852851 | Active, not recruiting | University of British Columbia | 2020-06-30 |
| NCT01818804 | The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01818804 | Completed | Aalborg University Hospital | 2015-12-31 |
| NCT01752634 | Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01752634 | Completed | Novartis | 2014-05-12 |
| NCT01695239 | A Study of Ixekizumab in Participants With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01695239 | Completed | Eli Lilly and Company | 2014-12-31 |
| NCT01690299 | Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis | https://ClinicalTrials.gov/show/NCT01690299 | Completed | Amgen | 2014-07-03 |
| NCT01680159 | A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis | https://ClinicalTrials.gov/show/NCT01680159 | Completed | Mitsubishi Tanabe Pharma Corporation | 2015-03-31 |
| NCT02024646 | Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02024646 | Completed | Amgen | 2015-10-31 |
| NCT01519089 | A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01519089 | Completed | Pfizer | 2014-01-31 |
| NCT01490450 | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy | https://ClinicalTrials.gov/show/NCT01490450 | Completed | Vitaeris INC | 2013-06-30 |
| NCT01465438 | HUmira in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01465438 | Completed | Glostrup University Hospital, Copenhagen | 2011-06-30 |
| NCT01463189 | Web-based Support to Manage Arthritis Pain | https://ClinicalTrials.gov/show/NCT01463189 | Completed | Inflexxion, Inc. | 2012-11-30 |
| NCT01392326 | Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT01392326 | Completed | Novartis | 2014-10-31 |
| NCT04304326 | Comparison of the Effectiveness of Functional Training Versus Resistance Exercises in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT04304326 | Recruiting | Federal University of São Paulo | 2020-04-02 |
| NCT04261010 | TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study | https://ClinicalTrials.gov/show/NCT04261010 | Recruiting | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2022-01-31 |
| NCT04209205 | Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT04209205 | Recruiting | Novartis | 2021-04-23 |
| NCT04200690 | Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases | https://ClinicalTrials.gov/show/NCT04200690 | Recruiting | University of Aarhus | 2022-07-31 |
| NCT04183881 | A Phase 4 Clinical Study of Brodalumab | https://ClinicalTrials.gov/show/NCT04183881 | Completed | Kyowa Kirin Co., Ltd. | 2017-01-10 |
| NCT04173039 | Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT04173039 | Completed | Association pour la Recherche Clinique et Immunologique | 2019-04-24 |
| NCT04152759 | Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects | https://ClinicalTrials.gov/show/NCT04152759 | Recruiting | Bio-Thera Solutions | 2020-04-01 |
| NCT04115839 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy | https://ClinicalTrials.gov/show/NCT04115839 | Recruiting | Gilead Sciences | 2022-02-28 |
| NCT04115748 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy | https://ClinicalTrials.gov/show/NCT04115748 | Active, not recruiting | Gilead Sciences | 2022-03-31 |
| NCT04110522 | Psoriatic Arthritis D2P Screening | https://ClinicalTrials.gov/show/NCT04110522 | Recruiting | University of Utah | 2022-01-31 |
| NCT04108468 | GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA) | https://ClinicalTrials.gov/show/NCT04108468 | Recruiting | The Leeds Teaching Hospitals NHS Trust | 2021-03-31 |
| NCT04106804 | Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker | https://ClinicalTrials.gov/show/NCT04106804 | Recruiting | University of Erlangen-Nürnberg Medical School | 2021-08-31 |
| NCT04065958 | Yoga-mindfulness for Chronic Arthritis Patients With Persistent Pain | https://ClinicalTrials.gov/show/NCT04065958 | Recruiting | Karolinska Institutet | 2021-06-30 |
| NCT04018599 | Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS | https://ClinicalTrials.gov/show/NCT04018599 | Completed | Fresenius Kabi SwissBioSim GmbH | 2020-03-17 |
| NCT04014413 | Safety and Efficacy of Fecal Microbiota Transplantation | https://ClinicalTrials.gov/show/NCT04014413 | Recruiting | Chinese University of Hong Kong | 2023-10-31 |
| NCT03963401 | A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03963401 | Active, not recruiting | Pfizer | 2020-04-06 |
| NCT03942783 | WORKWELL: Testing Work Advice for People With Arthritis | https://ClinicalTrials.gov/show/NCT03942783 | Recruiting | University of Salford | 2021-07-30 |
| NCT03932110 | Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels | https://ClinicalTrials.gov/show/NCT03932110 | Completed | Istanbul Medeniyet University | 2019-06-01 |
| NCT03881059 | Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT03881059 | Active, not recruiting | Bristol-Myers Squibb | 2021-01-28 |
| NCT03347110 | A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03347110 | Active, not recruiting | UCB Pharma | 2020-11-30 |
| NCT03853395 | BIOTIPRA: BIOmarker-guided Treatment Decisions In Psoriatic and Rheumatoid Arthritis | https://ClinicalTrials.gov/show/NCT03853395 | Recruiting | University of Manchester | 2021-02-28 |
| NCT03797872 | Psoriatic Oligoarthritis Intervention With Symptomatic thErapy | https://ClinicalTrials.gov/show/NCT03797872 | Recruiting | University of Oxford | 2021-09-30 |
| NCT03783026 | A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03783026 | Recruiting | Amgen | 2021-06-01 |
| NCT03769168 | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | https://ClinicalTrials.gov/show/NCT03769168 | Recruiting | Novartis | 2024-10-02 |
| NCT03747939 | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. | https://ClinicalTrials.gov/show/NCT03747939 | Recruiting | Amgen | 2021-01-28 |
| NCT03739853 | Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial | https://ClinicalTrials.gov/show/NCT03739853 | Recruiting | University of Oxford | 2022-02-28 |
| NCT03737045 | Psoriatic Arthritis and Psoriasis Treatment Decision Aid | https://ClinicalTrials.gov/show/NCT03737045 | Recruiting | University of Pennsylvania | 2020-12-01 |
| NCT03693833 | CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. | https://ClinicalTrials.gov/show/NCT03693833 | Recruiting | Aalborg University Hospital | 2020-12-01 |
| NCT03675308 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy | https://ClinicalTrials.gov/show/NCT03675308 | Active, not recruiting | AbbVie | 2020-10-01 |
| NCT03671148 | A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) | https://ClinicalTrials.gov/show/NCT03671148 | Active, not recruiting | AbbVie | 2020-06-19 |
| NCT03626038 | PMCF Study of the A.L.P.S. Proximal Humerus Plating System | https://ClinicalTrials.gov/show/NCT03626038 | Recruiting | Zimmer Biomet | 2021-01-31 |
| NCT03598751 | Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03598751 | Active, not recruiting | Biocad | 2020-04-30 |
| NCT03552276 | A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. | https://ClinicalTrials.gov/show/NCT03552276 | Active, not recruiting | Sun Pharma Global FZE | 2023-06-30 |
| NCT03486613 | PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis | https://ClinicalTrials.gov/show/NCT03486613 | Completed | Aalborg University Hospital | 2019-09-12 |
| NCT03455166 | Identification of New Prognostic Markers in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03455166 | Completed | Istituto Ortopedico Galeazzi | 2016-04-30 |
| NCT03419650 | Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) | https://ClinicalTrials.gov/show/NCT03419650 | Active, not recruiting | IRIS Research and Development, LLC | 2020-10-31 |
| NCT01212770 | PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01212770 | Completed | Amgen | 2012-08-21 |
| NCT01212757 | PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01212757 | Completed | Amgen | 2012-07-26 |
| NCT01199809 | A Study of RO5310074 in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01199809 | Completed | Hoffmann-La Roche | 2012-02-29 |
| NCT01198509 | Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) | https://ClinicalTrials.gov/show/NCT01198509 | Completed | NYU Langone Health | 2013-01-31 |
| NCT01172938 | Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01172938 | Completed | Amgen | 2012-04-27 |
| NCT01169844 | Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01169844 | Completed | Novartis | 2012-11-30 |
| NCT01147874 | Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice | https://ClinicalTrials.gov/show/NCT01147874 | Completed | Pfizer | 2011-07-31 |
| NCT01106079 | TIght COntrol of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01106079 | Completed | University of Leeds | 2012-07-31 |
| NCT01087788 | Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01087788 | Completed | UCB Pharma | 2011-11-30 |
| NCT01077362 | A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents | https://ClinicalTrials.gov/show/NCT01077362 | Completed | Janssen Research & Development, LLC | 2012-03-31 |
| NCT01009086 | A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01009086 | Completed | Janssen Research & Development, LLC | 2011-10-31 |
| NCT00946686 | To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions | https://ClinicalTrials.gov/show/NCT00946686 | Completed | Sandoz | 2002-09-30 |
| NCT03736161 | Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03736161 | Completed | Globe Pharmaceuticals Limited | 2019-09-28 |
| NCT02849795 | Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02849795 | Completed | Centre Hospitalier Universitaire de Besancon | 2017-10-17 |
| NCT00809614 | Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00809614 | Completed | Novartis | 2010-12-31 |
| NCT01877668 | Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study | https://ClinicalTrials.gov/show/NCT01877668 | Completed | Pfizer | 2015-12-18 |
| NCT03074656 | The Norwegian Drug Monitoring Study | https://ClinicalTrials.gov/show/NCT03074656 | Active, not recruiting | Diakonhjemmet Hospital | 2021-01-01 |
| NCT02019602 | A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta | https://ClinicalTrials.gov/show/NCT02019602 | Completed | UCB Pharma | 2016-10-31 |
| NCT01860976 | Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01860976 | Active, not recruiting | Bristol-Myers Squibb | 2015-07-14 |
| NCT00659412 | A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00659412 | Completed | Astellas Pharma Inc | 2005-03-31 |
| NCT00646386 | Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00646386 | Completed | Abbott | 2004-04-30 |
| NCT00646178 | Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy | https://ClinicalTrials.gov/show/NCT00646178 | Completed | Abbott | 2004-03-31 |
| NCT00643526 | A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector | https://ClinicalTrials.gov/show/NCT00643526 | Completed | Centocor, Inc. | 2008-01-31 |
| NCT00509678 | Rituxan With or Without Methotrexate in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00509678 | Completed | Swedish Medical Center | 2010-01-31 |
| NCT00462072 | Centocor Microarray Study of Patients | https://ClinicalTrials.gov/show/NCT00462072 | Completed | University of Rochester | 2010-06-30 |
| NCT00456092 | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00456092 | Completed | Amgen | 2009-05-09 |
| NCT00432406 | Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00432406 | Completed | Chinese University of Hong Kong | 2009-03-31 |
| NCT00367237 | Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) | https://ClinicalTrials.gov/show/NCT00367237 | Completed | Merck Sharp & Dohme Corp. | 2008-03-31 |
| NCT00317499 | Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis | https://ClinicalTrials.gov/show/NCT00317499 | Completed | Amgen | 2002-06-30 |
| NCT00267956 | An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00267956 | Completed | Centocor, Inc. | 2007-03-31 |
| NCT00265096 | A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00265096 | Completed | Centocor, Inc. | 2007-05-31 |
| NCT00245960 | Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00245960 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-05-31 |
| NCT00235885 | Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT00235885 | Completed | Abbott | NA |
| NCT00195689 | Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00195689 | Completed | Abbott | NA |
| NCT00161655 | Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis | https://ClinicalTrials.gov/show/NCT00161655 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-08-31 |
| NCT00133315 | TNFalfa Blocking Treatment of Spondylarthropathies | https://ClinicalTrials.gov/show/NCT00133315 | Completed | Hvidovre University Hospital | NA |
| NCT00127842 | REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) | https://ClinicalTrials.gov/show/NCT00127842 | Completed | Amgen | 2005-08-31 |
| NCT00126724 | Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects | https://ClinicalTrials.gov/show/NCT00126724 | Completed | Targeted Genetics Corporation | 2008-10-31 |
| NCT00111124 | Enbrel® in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00111124 | Completed | Amgen | NA |
| NCT00051662 | Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00051662 | Completed | XOMA (US) LLC | NA |
| NCT00051623 | A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00051623 | Completed | Centocor, Inc. | NA |
| NCT00001422 | A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00001422 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00023205 | Impact of Literacy Level on Patient Education and Health Among People With Arthritis | https://ClinicalTrials.gov/show/NCT00023205 | Completed | Brigham and Women’s Hospital | 2006-08-31 |
| NCT00427362 | A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) | https://ClinicalTrials.gov/show/NCT00427362 | Completed | Abbott | 2007-05-31 |
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT02028169 | To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA) | https://ClinicalTrials.gov/show/NCT02028169 | Completed | AbbVie | 2016-04-30 |
| NCT03399708 | Immune Metabolic Associations in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03399708 | Completed | NHS Greater Glasgow and Clyde | 2019-10-12 |
| NCT03823924 | Changes in Body Composition Under Ustekinumab in PsA | https://ClinicalTrials.gov/show/NCT03823924 | Recruiting | University Hospital, Lille | 2022-07-31 |
| NCT03336281 | A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab | https://ClinicalTrials.gov/show/NCT03336281 | Completed | Janssen Cilag S.A.S. | 2020-04-07 |
| NCT03330769 | Ultrasound in Psoriatic Arthritis Treatment | https://ClinicalTrials.gov/show/NCT03330769 | Recruiting | University of Cagliari | 2020-02-28 |
| NCT03248284 | Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons | https://ClinicalTrials.gov/show/NCT03248284 | Recruiting | Odense University Hospital | 2021-06-21 |
| NCT03223012 | Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service | https://ClinicalTrials.gov/show/NCT03223012 | Completed | AbbVie | 2019-02-28 |
| NCT03106051 | Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions | https://ClinicalTrials.gov/show/NCT03106051 | Active, not recruiting | Amgen | 2018-07-31 |
| NCT03011242 | DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA | https://ClinicalTrials.gov/show/NCT03011242 | Recruiting | University of Rochester | 2020-08-31 |
| NCT03006198 | Tracking Biologics Along the Silk Road | https://ClinicalTrials.gov/show/NCT03006198 | Completed | Janssen Pharmaceutica N.V., Belgium | 2018-12-01 |
| NCT02988674 | A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation | https://ClinicalTrials.gov/show/NCT02988674 | Completed | AbbVie | 2019-10-16 |
| NCT02984020 | Korean Post-marketing Surveillance for Xeljanz | https://ClinicalTrials.gov/show/NCT02984020 | Recruiting | Pfizer | 2020-06-09 |
| NCT02925338 | National Observational Study On The Use Of Inflectraâ„¢ An Infliximab Biosimilar In Real Life | https://ClinicalTrials.gov/show/NCT02925338 | Recruiting | Pfizer | 2020-09-23 |
| NCT02886689 | C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France | https://ClinicalTrials.gov/show/NCT02886689 | Completed | Central Hospital, Nancy, France | 2010-12-31 |
| NCT02875184 | A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands | https://ClinicalTrials.gov/show/NCT02875184 | Recruiting | Amgen | 2022-06-30 |
| NCT02750800 | Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie’s Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) | https://ClinicalTrials.gov/show/NCT02750800 | Completed | AbbVie | 2018-04-03 |
| NCT02605642 | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade | https://ClinicalTrials.gov/show/NCT02605642 | Completed | Pfizer | 2018-12-31 |
| NCT00508547 | Psoriasis Longitudinal Assessment and Registry (PSOLAR) | https://ClinicalTrials.gov/show/NCT00508547 | Recruiting | Janssen Scientific Affairs, LLC | 2021-05-31 |
| NCT03396679 | Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission | https://ClinicalTrials.gov/show/NCT03396679 | Completed | University Hospital, Montpellier | 2018-06-29 |
| NCT02556034 | Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. | https://ClinicalTrials.gov/show/NCT02556034 | Completed | Centre de Rhumatologie de l’Est du Québec | 2018-11-16 |
| NCT02486302 | A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. | https://ClinicalTrials.gov/show/NCT02486302 | Completed | Pfizer | 2017-12-11 |
| NCT02470481 | A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics | https://ClinicalTrials.gov/show/NCT02470481 | Completed | Janssen Research & Development, LLC | 2016-07-31 |
| NCT02414633 | Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI]) | https://ClinicalTrials.gov/show/NCT02414633 | Completed | AbbVie | 2017-03-13 |
| NCT02413749 | DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA | https://ClinicalTrials.gov/show/NCT02413749 | Completed | University of Rochester | 2016-12-28 |
| NCT02402894 | Follow-up of Person-centered Care of Young Adults With Rheumatic Disease | https://ClinicalTrials.gov/show/NCT02402894 | Active, not recruiting | Vastra Gotaland Region | 2020-12-31 |
| NCT02361385 | PBR28 PET and Inflammatory Arthritis | https://ClinicalTrials.gov/show/NCT02361385 | Completed | University of Oxford | 2017-07-31 |
| NCT01316224 | Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment | https://ClinicalTrials.gov/show/NCT01316224 | Completed | AbbVie | 2014-04-30 |
| NCT01313858 | A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) | https://ClinicalTrials.gov/show/NCT01313858 | Completed | Merck Sharp & Dohme Corp. | 2015-09-30 |
| NCT01282372 | Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab | https://ClinicalTrials.gov/show/NCT01282372 | Completed | AbbVie | 2014-07-31 |
| NCT01273519 | Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab | https://ClinicalTrials.gov/show/NCT01273519 | Completed | AbbVie | 2013-01-31 |
| NCT03378336 | Psoriatic Arthritis Research Collaborative: Biologic Sub-Study | https://ClinicalTrials.gov/show/NCT03378336 | Recruiting | University of Pennsylvania | 2021-01-01 |
| NCT01931644 | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | https://ClinicalTrials.gov/show/NCT01931644 | Recruiting | Sanguine Biosciences | 2025-08-31 |
| NCT01845818 | Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium | https://ClinicalTrials.gov/show/NCT01845818 | Completed | AbbVie | 2017-06-23 |
| NCT01833468 | Functional Limitations Due To The Foot Involvement In Spondyloarthritis | https://ClinicalTrials.gov/show/NCT01833468 | Completed | Vakif Gureba Training and Research Hospital | 2013-04-30 |
| NCT01797224 | OTIS Autoimmune Diseases in Pregnancy Project | https://ClinicalTrials.gov/show/NCT01797224 | Recruiting | University of California, San Diego | 2020-01-31 |
| NCT01768858 | Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn’s Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice | https://ClinicalTrials.gov/show/NCT01768858 | Completed | AbbVie | 2017-08-13 |
| NCT01654198 | PET/CT in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01654198 | Completed | University of Pennsylvania | 2020-05-31 |
| NCT01559038 | Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01559038 | Completed | AbbVie | 2019-11-19 |
| NCT01474876 | Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01474876 | Completed | AbbVie | 2014-05-31 |
| NCT04426747 | Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis | https://ClinicalTrials.gov/show/NCT04426747 | Recruiting | Groupe Hospitalier Pitie-Salpetriere | 2019-11-16 |
| NCT04345159 | Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease | https://ClinicalTrials.gov/show/NCT04345159 | Active, not recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 2020-04-30 |
| NCT04335747 | COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases | https://ClinicalTrials.gov/show/NCT04335747 | Recruiting | Aalborg University Hospital | 2021-08-01 |
| NCT04277832 | Evaluating of New Screening Tool for Arthritis* in Psoriasis | https://ClinicalTrials.gov/show/NCT04277832 | Recruiting | Bezmialem Vakif University | 2020-08-31 |
| NCT04191395 | Evolution and Treatments of Chronic Inflammatory Systemic Diseases | https://ClinicalTrials.gov/show/NCT04191395 | Recruiting | Centre Hospitalier Universitaire de Besancon | 2029-12-31 |
| NCT04190758 | GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden | https://ClinicalTrials.gov/show/NCT04190758 | Recruiting | Vastra Gotaland Region | 2039-12-31 |
| NCT04190108 | Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis. | https://ClinicalTrials.gov/show/NCT04190108 | Completed | Hospital of Prato | 2018-12-31 |
| NCT04089514 | A Real-world Study of Imraldi® Use | https://ClinicalTrials.gov/show/NCT04089514 | Recruiting | Biogen | 2021-06-30 |
| NCT03986918 | Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System | https://ClinicalTrials.gov/show/NCT03986918 | Recruiting | Ortho Development Corporation | 2023-06-30 |
| NCT03955861 | Ultrasound Enthesitis Response in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03955861 | Recruiting | Belfast Health and Social Care Trust | 2020-02-29 |
| NCT03953378 | CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03953378 | Completed | Hospices Civils de Lyon | 2018-12-31 |
| NCT03885089 | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg “Pfizer” Drug Use Investigation (Psoriasis) | https://ClinicalTrials.gov/show/NCT03885089 | Recruiting | Pfizer | 2023-03-13 |
| NCT03835780 | The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study | https://ClinicalTrials.gov/show/NCT03835780 | Completed | Momentum Data | 2019-08-01 |
| NCT03828045 | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment | https://ClinicalTrials.gov/show/NCT03828045 | Recruiting | Amgen | 2020-08-06 |
| NCT03816917 | Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral | https://ClinicalTrials.gov/show/NCT03816917 | Enrolling by invitation | Radboud University | 2021-12-01 |
| NCT03780504 | Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece | https://ClinicalTrials.gov/show/NCT03780504 | Recruiting | Genesis Pharma S.A. | 2020-10-01 |
| NCT03768271 | APACHE Cohort (A Psoriatic Arthritis CoHort) | https://ClinicalTrials.gov/show/NCT03768271 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2026-03-01 |
| NCT03662919 | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study | https://ClinicalTrials.gov/show/NCT03662919 | Recruiting | Biogen | 2022-06-30 |
| NCT03620188 | Treatment Goals in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03620188 | Active, not recruiting | Johns Hopkins University | 2020-12-31 |
| NCT03608657 | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE | https://ClinicalTrials.gov/show/NCT03608657 | Active, not recruiting | Amgen | 2021-02-21 |
| NCT03533569 | Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis | https://ClinicalTrials.gov/show/NCT03533569 | Recruiting | St George’s, University of London | 2021-04-02 |
| NCT03531073 | Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT03531073 | Recruiting | University of Oxford | 2023-04-30 |
| NCT03496831 | Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs | https://ClinicalTrials.gov/show/NCT03496831 | Completed | Rigshospitalet, Denmark | 2017-12-31 |
| NCT03452735 | Fertility Study of Women With Chronic Inflammatory Rheumatism | https://ClinicalTrials.gov/show/NCT03452735 | Recruiting | University Hospital, Toulouse | 2019-07-31 |
| NCT03419143 | Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants | https://ClinicalTrials.gov/show/NCT03419143 | Recruiting | Bristol-Myers Squibb | 2020-03-30 |
| NCT03411057 | Mindfulness Based Stress Reduction in Rheumatic Diseases | https://ClinicalTrials.gov/show/NCT03411057 | Enrolling by invitation | Johns Hopkins University | 2021-01-18 |
| NCT01163916 | Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care | https://ClinicalTrials.gov/show/NCT01163916 | Completed | Abbott | 2011-11-30 |
| NCT01155570 | Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) | https://ClinicalTrials.gov/show/NCT01155570 | Completed | AbbVie | 2012-07-31 |
| NCT01139918 | Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT01139918 | Completed | Innovaderm Research Inc. | 2014-07-31 |
| NCT01123265 | National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study | https://ClinicalTrials.gov/show/NCT01123265 | Completed | University of Rochester | 2014-06-30 |
| NCT01111240 | Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice | https://ClinicalTrials.gov/show/NCT01111240 | Completed | AbbVie | 2013-12-31 |
| NCT01083693 | Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs | https://ClinicalTrials.gov/show/NCT01083693 | Completed | Abbott | 2010-06-30 |
| NCT01083121 | Surveillance of Humira Injection in Korean Patients | https://ClinicalTrials.gov/show/NCT01083121 | Completed | AbbVie | 2012-06-30 |
| NCT01081717 | Golimumab Safety and Surveillance Program Using the Ingenix NHI Database | https://ClinicalTrials.gov/show/NCT01081717 | Completed | Janssen Biotech, Inc. | 2015-05-31 |
| NCT01078402 | EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries | https://ClinicalTrials.gov/show/NCT01078402 | Completed | AbbVie | 2011-11-30 |
| NCT01060098 | T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade | https://ClinicalTrials.gov/show/NCT01060098 | Completed | Imperial College London | 2012-12-31 |
| NCT00998829 | Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis | https://ClinicalTrials.gov/show/NCT00998829 | Completed | Pfizer | 2012-05-31 |
| NCT00963313 | A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00963313 | Completed | Instituto de Investigacion Biomedica de A Coruna | 2012-06-30 |
| NCT00938015 | Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00938015 | Completed | Pfizer | 2012-04-30 |
| NCT00902005 | Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment | https://ClinicalTrials.gov/show/NCT00902005 | Completed | Revmatismesykehuset AS | 2011-06-30 |
| NCT00884468 | Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00884468 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2008-12-31 |
| NCT03096990 | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium | https://ClinicalTrials.gov/show/NCT03096990 | Completed | Amgen | 2018-12-27 |
| NCT02627768 | A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT02627768 | Active, not recruiting | Janssen Pharmaceutica N.V., Belgium | 2021-06-30 |
| NCT01078558 | A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) | https://ClinicalTrials.gov/show/NCT01078558 | Completed | AbbVie | 2018-01-11 |
| NCT00760669 | An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants | https://ClinicalTrials.gov/show/NCT00760669 | Completed | Janssen Korea, Ltd., Korea | 2011-04-30 |
| NCT00751387 | Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia | https://ClinicalTrials.gov/show/NCT00751387 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-09-30 |
| NCT00741793 | Biologic Treatment Registry Across Canada | https://ClinicalTrials.gov/show/NCT00741793 | Completed | Janssen Inc. | 2018-06-27 |
| NCT00727298 | Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) | https://ClinicalTrials.gov/show/NCT00727298 | Completed | Merck Sharp & Dohme Corp. | 2011-08-31 |
| NCT00725296 | Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264) | https://ClinicalTrials.gov/show/NCT00725296 | Completed | Merck Sharp & Dohme Corp. | 2010-07-31 |
| NCT00683384 | Study Evaluating the Safety of Enbrel (Etanercept) | https://ClinicalTrials.gov/show/NCT00683384 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-10-31 |
| NCT00658827 | Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis | https://ClinicalTrials.gov/show/NCT00658827 | Completed | Janssen Biotech, Inc. | 2016-09-30 |
| NCT00580632 | Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00580632 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-09-30 |
| NCT00451243 | Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment | https://ClinicalTrials.gov/show/NCT00451243 | Completed | National Taiwan University Hospital | NA |
| NCT00303186 | Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy | https://ClinicalTrials.gov/show/NCT00303186 | Completed | Pfizer | 2011-06-30 |
| NCT00293722 | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists | https://ClinicalTrials.gov/show/NCT00293722 | Completed | Pfizer | 2013-02-28 |
| NCT00293709 | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists | https://ClinicalTrials.gov/show/NCT00293709 | Completed | Pfizer | 2013-02-28 |
| NCT00195377 | Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain | https://ClinicalTrials.gov/show/NCT00195377 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-04-30 |
| NCT00001291 | Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions | https://ClinicalTrials.gov/show/NCT00001291 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00001420 | Study of Psoriatic Arthritis | https://ClinicalTrials.gov/show/NCT00001420 | Completed | National Institutes of Health Clinical Center (CC) | NA |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03374527 | Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis | https://ClinicalTrials.gov/show/NCT03374527 | Completed | Istituto Ortopedico Galeazzi | 2018-01-30 |
| NCT03214263 | Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases | https://ClinicalTrials.gov/show/NCT03214263 | Recruiting | Rigshospitalet, Denmark | 2024-12-31 |
| NCT03119805 | Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. | https://ClinicalTrials.gov/show/NCT03119805 | Completed | Groupe Hospitalier Pitie-Salpetriere | 2018-01-30 |
| NCT02775500 | Apremilast Pregnancy Exposure Registry | https://ClinicalTrials.gov/show/NCT02775500 | Recruiting | University of California, San Diego | 2022-02-28 |
| NCT02530268 | The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry | https://ClinicalTrials.gov/show/NCT02530268 | Enrolling by invitation | Corrona, LLC. | 2100-12-31 |
| NCT02103361 | Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project | https://ClinicalTrials.gov/show/NCT02103361 | Recruiting | University of California, San Diego | 2024-12-31 |
| NCT01965132 | Korean College of Rheumatology Biologics Registry | https://ClinicalTrials.gov/show/NCT01965132 | Recruiting | Seoul National University Hospital | 2024-12-31 |
| NCT01848028 | PsoBest - The German Psoriasis Registry | https://ClinicalTrials.gov/show/NCT01848028 | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 2025-12-31 |
| NCT04347798 | IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT | https://ClinicalTrials.gov/show/NCT04347798 | Enrolling by invitation | University of Alberta | 2021-04-30 |
| NCT03470688 | Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents | https://ClinicalTrials.gov/show/NCT03470688 | Recruiting | Opal Rheumatology Ltd. | 2021-06-01 |
| NCT03456206 | Chronic Inflammatory Disease, Lifestyle and Risk of Disease | https://ClinicalTrials.gov/show/NCT03456206 | Active, not recruiting | University of Southern Denmark | 2019-07-01 |
| NCT03840928 | AR-Power Patient Powered Research Network | https://ClinicalTrials.gov/show/NCT03840928 | Recruiting | Global Healthy Living Foundation | 2025-03-01 |
| NCT03173144 | Chronic Inflammatory Disease, Lifestyle and Treatment Response | https://ClinicalTrials.gov/show/NCT03173144 | Recruiting | University of Southern Denmark | 2019-03-31 |
| NCT04402086 | Rheumatology Patient Registry and Biorepository | https://ClinicalTrials.gov/show/NCT04402086 | Recruiting | Yale University | 2030-06-01 |